1. 235P Multiplexed imaging reveals the immunomodulatory cGAS as a predictor of response in patients with malignant pleural mesothelioma. (December 2022) Authors: Laure, A.; Silina, K.; Kirschner, M.; Opitz, I.; Hiltbrunner, S.; Curioni-Fontecedro, A. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry. Issue 1 (December 2016) Authors: Kaifie, A.; Kirschner, M.; Wolf, D.; Maintz, C.; Hänel, M.; Gattermann, N.; Gökkurt, E.; Platzbecker, U.; Hollburg, W.; Göthert, J.; Parmentier, S.; Lang, F.; Hansen, R.; Isfort, S.; Schmitt, K.; Jost, E.; Serve, H.; Ehninger, G.; Berdel, W.; Brümmendorf, T. Journal: Journal of hematology & oncology Issue: Volume 9:Issue 1(2016) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Overnight switching from oxcarbazepine to eslicarbazepine acetate: an observational study. (22nd July 2016) Authors: Schmid, E.; Kuchukhidze, G.; Kirschner, M.; Leitinger, M.; Höfler, J.; Rohracher, A.; Kalss, G.; Wendling, A.‐S.; Steinhoff, B. J.; Trinka, E. Journal: Acta neurologica Scandinavica Issue: Volume 135:Number 4(2017:Apr.) Page Start: 449 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. PO-1372: Feasibility of treatment planning on contrast enhanced CTs for HN cancer. (November 2020) Authors: Gober, M.; Riegler, A.; Zagler, N.; Cires, D.; Beck, F.; Kirschner, M.; Steiner, E.; Metz, M. Journal: Radiotherapy and oncology Issue: Volume 152(2020)Supplement 1 Page Start: S729 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗